AccurEdit Therapeutics
Going beyond disease management
Jiangsu, United States · Founded 2021 · $75.0M raised
- Headquarters
- Jiangsu
- Founded
- 2021
- Business Model
- B2B
- Website
- accuredit.com
- Total Funding
- $75.0M
- Last Round
- $75.0M Series AAug 2023
- Rounds
- 1
About
AccurEdit Therapeutics is committed to developing cures for severe and life-threatening diseases through in vivo gene editing. The company has established an industry-leading end-to-end technology platform focused on RNA synthesis, editing, and delivery technologies. In October 2023, AccurEdit became the first company in China to demonstrate safe and effective systemic CRISPR gene editing in humans. Its lead program ART001 is an LNP-delivered in vivo gene editing therapy and received FDA RMAT designation. AccurEdit follows a patient-oriented philosophy pursuing single-dose curative therapy via a highly efficient technology platform.
Summary
AccurEdit Therapeutics is a Biotechnology company based in Jiangsu, United States, founded in 2021. It has raised $75.0M in total across 1 round, most recently a $75.0M Series A round in Aug 2023.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2023
Similar Companies
Leading innovative radiopharmaceutical company in China developing next-generation radiopharmaceu...
Clinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Nativ...
Clinical-stage ophthalmic gene therapy company developing AAV-based treatments for rare and preva...
Belgian agricultural biotech company developing microbial-based biocontrol and biostimulant produ...
Biotech company developing novel GPCR-targeting therapeutics using conformation-specific nanobodies.
Biopharmaceutical company developing multispecific antibody therapies for retinal and complex dis...